Recursion Pharmaceuticals, Inc.

NasdaqGS:RXRX Stock Report

Mkt Cap: US$1.8b

Recursion Pharmaceuticals Financial Health

How is Recursion Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RXRX's short term assets ($481.6M) exceed its short term liabilities ($83.0M).

Long Term Liabilities: RXRX's short term assets ($481.6M) exceed its long term liabilities ($140.5M).


Debt to Equity History and Analysis

Debt Level: RXRX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if RXRX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RXRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: RXRX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 28.2% each year.


Discover healthy companies